The present invention provides a non-drug cardio-cerebrovascular disease therapeutic apparatus. A waveform diagram of a pulse current for generating a pulse electromagnetic field includes four characteristic bands in a cycle range of 360° and reciprocates circularly: an abrupt-rising band T1 where a current intensity I(t) abruptly rises, wherein a highest value thereof is slightly lower than a maximum value Imax of an output current; a first slow-rising band T2 where the current intensity I(t) slowly rises to the maximum value Imax; an abrupt-decreasing band T3 where the current intensity I(t) abruptly decreases, wherein a minimum value Imin thereof is slightly higher than a minimum value (Imin) of the output current; and a slow-decreasing band T4 where the current intensity I(t) slowly decreases to the minimum value (Imin). The non-drug cardio-cerebrovascular disease therapeutic apparatus provided by the present invention can significantly improve and treat cardio-cerebrovascular diseases and achieve obvious effects.

A magnet band for production of magnetized water according to an embodiment of the present disclosure is easy to carry and convenient to use so that a user can easily magnetically activate and drink a beverage, and has a structure with reduced production cost so that many people can inexpensively and widely use the magnet band.

A magnet band for production of magnetized water according to an embodiment of the present disclosure is easy to carry and convenient to use so that a user can easily magnetically activate and drink a beverage, and has a structure with reduced production cost so that many people can inexpensively and widely use the magnet band.

The technology disclosed herein relates to a transcutaneous irradiation device having a top portion and a bottom portion. The top portion may include one or more transcutaneous irradiation modules configured to be arranged on a head of a user, the top transcutaneous irradiation modules including a top pulsed laser source. The bottom portion may include one or more transcutaneous irradiation modules configured to be arranged on an abdomen of the user, the top transcutaneous irradiation modules including a bottom pulsed laser source. A modulation frequency may be applied to the top and bottom irradiation modules such that the top and bottom pulse laser sources are subjected to a double pulse.

The technology disclosed herein relates to a transcutaneous irradiation device having a top portion and a bottom portion. The top portion may include one or more transcutaneous irradiation modules configured to be arranged on a head of a user, the top transcutaneous irradiation modules including a top pulsed laser source. The bottom portion may include one or more transcutaneous irradiation modules configured to be arranged on an abdomen of the user, the top transcutaneous irradiation modules including a bottom pulsed laser source. A modulation frequency may be applied to the top and bottom irradiation modules such that the top and bottom pulse laser sources are subjected to a double pulse.

A Closed Loop Hybrid Modulation Methodology, including the following four methods of neural stimulation: METHOD 1: A priming electrical signal followed by a second magnetic signal. METHOD 2: A magnetic priming signal followed by a second electrical signal. METHOD 3: A priming magnetic signal followed by a second magnetic signal. METHOD 4: A priming hybrid electric and magnetic signal followed by a second hybrid electric and magnetic signal.

A Closed Loop Hybrid Modulation Methodology, including the following four methods of neural stimulation: METHOD 1: A priming electrical signal followed by a second magnetic signal. METHOD 2: A magnetic priming signal followed by a second electrical signal. METHOD 3: A priming magnetic signal followed by a second magnetic signal. METHOD 4: A priming hybrid electric and magnetic signal followed by a second hybrid electric and magnetic signal.

A method for directing therapeutic nanoparticle-labeled cells to selected locations within the body and/or for retaining therapeutic nanoparticle-labeled cells at selected locations within the body, the method comprising: providing an article comprising a body of material configured to be secured about the body of a patient and having a plurality of pockets thereon, wherein each pocket is sized to receive and retain one or more magnets therein; injecting therapeutic USPIO nanoparticle-containing cells into a target therapy site; securing the article to the body of the patient; and inserting at least one magnet into at least one pocket so as to provide a desired magnetic field for further directing therapeutic nanoparticle-labelled cells to a target therapy site and/or for retaining therapeutic nanoparticle-labeled cells at the target therapy site.

Photobiomodulation therapy (PBMT) can be applied to a tender area on a subject's body to treat fibromyalgia. A light source device can be contacted to a subject's skin proximal to a tender area on the subject's body. A light signal (with wavelengths from the red to infrared part of the spectrum) can be applied in at least one of a pulsed operating mode, a continuous operating mode, and a super-pulsed operating mode through the light source device to the tender area. The light signal is applied for a time sufficient to stimulate a phototherapeutic response in the tender area to treat fibromyalgia.

Photobiomodulation therapy (PBMT) can be applied to a tender area on a subject's body to treat fibromyalgia. A light source device can be contacted to a subject's skin proximal to a tender area on the subject's body. A light signal (with wavelengths from the red to infrared part of the spectrum) can be applied in at least one of a pulsed operating mode, a continuous operating mode, and a super-pulsed operating mode through the light source device to the tender area. The light signal is applied for a time sufficient to stimulate a phototherapeutic response in the tender area to treat fibromyalgia.